Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of ISB 830 in Adult Subjects With Moderate to Severe Atopic Dermatitis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of ISB 830 in Adult Subjects With Moderate to Severe Atopic Dermatitis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telazorlimab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms OXFORAD TM
  • Sponsors Glenmark Pharmaceuticals Ltd; Ichnos Sciences
  • Most Recent Events

    • 02 Jun 2022 Status changed from active, no longer recruiting to completed.
    • 21 Aug 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.
    • 03 May 2021 Primary endpoint has been met. (Percentage change from baseline in Eczema Area and Severity Index (EASI) score), according to an Ichnos Sciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top